Huawei launches new Diabetes Risk Study for smartwatches

Huawei has announced a new blood glucose-related feature for its smartwatches. This health tracking tool was announced at the World Health Expo Dubai 2026 and has since been promoted on the brand’s social media.

The Huawei non-invasive blood glucose monitoring tool is called Diabetes Risk Study. It uses a smartwatch’s photoplethysmography (PPG) technology alongside other sensors, rather than taking direct blood sugar measurements like a continuous glucose monitor. As such, it is said to detect possible signs of diabetes or prediabetes using other data points. This method appears to be grounded in research which has shown a link between resting heart rate and diabetes.

Huawei’s Diabetes Risk Study requires smartwatch users to consistently wear their device for between three and fourteen days. Once the wearable has gathered sufficient data, you are given a Low, Medium or High risk rating. For the latter two, users are advised to speak to a medical professional for further assessment and advice.

According to Huawei’s Instagram post, the Diabetes Risk Study feature is now live on the Watch GT 6 Pro smartwatch (curr. €315.95 at Amazon DE). However, it has yet to appear in the change log of any software releases for this wearable, which was last updated in December 2025. The tool is also expected to roll out to some other Huawei smartwatches in the future.